Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444611 | 0.94 | SIGMAR1 (0.49) | MEN1KMT2ADRD2DRD3POLB | |
| SCHEMBL17444594 | 0.94 | MEN1 (0.46) | MEN1KMT2ADRD2DRD3POLB | |
| SCHEMBL17444539 | 0.93 | MEN1 (0.57) | MEN1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL17444671 | 0.92 | DRD2 (0.51) | MEN1KMT2ADRD2DRD3POLB | |
| SCHEMBL17444578 | 0.91 | DRD2 (0.51) | MEN1KMT2ADRD2DRD3POLB | |
| SCHEMBL17444605 | 0.90 | MEN1 (0.51) | MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL17444677 | 0.90 | MEN1 (0.44) | MEN1KMT2ADRD2DRD3POLB | |
| SCHEMBL17444680 | 0.89 | MEN1 (0.51) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL17444534 | 0.88 | MEN1 (0.49) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17444535 | 0.88 | DRD2 (0.51) | MEN1KMT2ADRD2DRD3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| EP-3169683-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | MEN1 2944/4885KMT2A 1730/4885DRD2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.